R Gralla
Overview
Explore the profile of R Gralla including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
29
Citations
1292
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Berman R, Davies A, Cooksley T, Gralla R, Carter L, Darlington E, et al.
Clin Oncol (R Coll Radiol)
. 2020 Aug;
32(11):781-788.
PMID: 32814649
The advent of new cancer therapies, alongside expected growth and ageing of the population, better survival rates and associated costs of care, is uncovering a need to more clearly define...
2.
Molassiotis A, Aapro M, Herrstedt J, Gralla R, Roila F
Support Care Cancer
. 2016 Aug;
25(1):267-269.
PMID: 27501964
No abstract available.
3.
Gralla R, Lichinitser M, van der Vegt S, Sleeboom H, Mezger J, Peschel C, et al.
Ann Oncol
. 2003 Sep;
14(10):1570-7.
PMID: 14504060
Background: Although all first-generation 5-HT(3) receptor antagonists demonstrate efficacy in preventing acute chemotherapy-induced nausea and vomiting (CINV), effective prevention of delayed CINV has not yet been achieved. This study compared...
4.
Schuler M, Herrmann R, De Greve J, Stewart A, Gatzemeier U, Stewart D, et al.
J Clin Oncol
. 2001 Mar;
19(6):1750-8.
PMID: 11251006
Purpose: To study the additional benefit from adenoviral p53 gene therapy in patients undergoing first-line chemotherapy for advanced non-small-cell lung cancer (NSCLC). Patients And Methods: Twenty-five patients with nonresectable NSCLC...
5.
Shepherd F, Dancey J, Ramlau R, Mattson K, Gralla R, ORourke M, et al.
J Clin Oncol
. 2000 May;
18(10):2095-103.
PMID: 10811675
Purpose: To evaluate whether treatment with single-agent docetaxel would result in longer survival than would best supportive care in patients with non-small-cell lung cancer who had previously been treated with...
6.
Gralla R, Harper P, Johnson S, Delgado F
Ann Oncol
. 1999 Dec;
10 Suppl 5:S47-51.
PMID: 10582139
The investigation of the activity of vinorelbine in non-small-cell lung cancer (NSCLC) has continued beyond the initial studies which established its single agent activity and defined the combination of vinorelbine...
7.
Gralla R, Harper P, Johnson S, Delgado F
Ann Oncol
. 1999 Dec;
10 Suppl 5:S41-5.
PMID: 10582138
Initial studies of vinorelbine (Navelbine) given as a single agent to patients with operable non-small-cell lung cancer (NSCLC) showed that overall response rates of the order of 30% could be...
8.
von Pawel J, Schiller J, Shepherd F, Fields S, Kleisbauer J, Chrysson N, et al.
J Clin Oncol
. 1999 Mar;
17(2):658-67.
PMID: 10080612
Purpose: Topotecan and cyclophosphamide, doxorubicin, and vincristine (CAV) were evaluated in a randomized, multicenter study of patients with small-cell lung cancer (SCLC) who had relapsed at least 60 days after...
9.
Hesketh P, Navari R, Grote T, Gralla R, Hainsworth J, KRIS M, et al.
J Clin Oncol
. 1996 Aug;
14(8):2242-9.
PMID: 8708713
Purpose: To assess the comparative antiemetic efficacy of single-dose intravenous (IV) dolasetron mesylate and ondansetron in preventing cisplatin-induced nausea and vomiting. Patients And Methods: Cancer patients (n = 609) receiving...
10.
Rusch V, Klimstra D, Venkatraman E, Oliver J, Martini N, Gralla R, et al.
Cancer Res
. 1995 Nov;
55(21):5038-42.
PMID: 7585548
The development of cisplatin-based induction chemotherapy followed by surgical resection or radiation has improved the poor prognosis of stage III non-small cell lung cancer (NSCLC). In vitro studies indicate that...